About Us Products Publications Contact


Aplagon originates from the research on mast cell–derived heparin proteoglycans (HEP-PG) performed by Riitta Lassila’s group at Wihuri Research Institute in Helsinki, Finland. HEP-PGs reside in vascular tissue and take locally part in vascular repair and control of coagulation.

Aplagon's products mimic the natural HEP-PGs and are tailored to have both antiplatelet (AP) and anticoagulant (AC) properties. APACs target the vascular injury site and have in several animal models shown to markedly inhibit thrombosis. APACs seem to also reduce bleeding risk in comparison with clinically widely used heparins.

      © Aplagon Oy 2015